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Introduction: Some recent studies have shown that citicoline improves clinical symptoms 
in patients with stroke. Citicoline's mechanism of action in improving the clinical 
symptoms is not recognized yet. The aim of this study was to evaluate the 
cerebrovascular hemodynamic status in patients with ischemic stroke treated with 
citicoline compared with the control group. 
Methods: In this study, 64 patients (20 male, 44 female) with supratentorial ischemic stroke were 
included. Patients underwent transcranial and extra cranial ultrasonography within 24 hours of 
admission and were divided into two equal groups (32 patients per group). One group was treated 
with citicoline (500 mg/day) and the second group was treated with placebo for one week. Then, 
patients underwent transcranial and extra cranial ultrasonography again. Data were analyzed by 
paired t-test and independent t-test. 
Results: In this study, no significant difference between the groups in terms of age, gender, 
cardiovascular factors and NIHSS was observed. Peak systolic velocity (PSV) in RCCA, RICA, 
RVA, LVA, and mean flow velocity (MFV) in RICA and LACA were significantly different 
between two groups. As there was no significant difference in confounding variables between the 
two groups, therefore, the difference in PSV and MFV between the groups may be due to citicoline. 
Conclusion: Prescription of citicoline for treatment of acute ischemic stroke is associated with 
hemodynamic changes in cerebral arteries. This finding can be one of the citicoline's mechanisms of 
action in ischemic stroke process. 
 
  
JKMU 
Journal of Kerman University of Medical Sciences, 2017; 24(6): 480-486 
 
The Effects of Citicoline on Cerebrovascular Hemodynamic Status in 
Ischemic Stroke Patients 
Rostam Seifaddini, M.D. 
1
 Akbar Hamze Moghadam, M.D. 
2
, Farhad Iranmanesh, M.D. 
3
, 
 Hamide Arvan, M.D. 
4
, Ahmad Naghibzadeh -Tahami, Ph.D. 
5
 
 
1- Assistant Professor of Neurology, Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran  
(Corresponding author; r.seifaddini@gmail.com) 
2- Professor of Neurology, Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran  
3- Professor of Neurology, Stroke Fellowship, Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran  
4- Resident of Neurology, Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran 
5- Ph.D. Candidate in Epidemiology, School of Public Health, Physiology Research Center, Institute of Neuropharmacology, Kerman University of 
Medical Sciences, Kerman, Iran 
Received: 27May, 2017  Accepted: 29 November, 2017 
 
 
ARTICLE INFO 
Original article 
 
Stroke 
Citicoline 
Doppler ultrasound 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Journal of Kerman University of Medical Sciences 2017, Vol. 24, Issue 6 
481 
Materials and Methods 
Effects of citicoline on cerebrovascular hemodynamic … Seifaddini, et al 
482 
 
Results 
Table 1. Demographic characteristics of the patients
Variable 
Placebo Intervention 
P-value 
Number Percent Number Percent 
Gender 
Male 19 59.4 25 78.1 
0.106 
Female 13 40.6 7 21.9 
Age 
<40 2 6.2 5 15.5 
0.676 40-65 15 46.9 16 50 
>65 15 46.9 11 44.5 
Diabetic Yes 15 46.9 11 34.4 0.309 
Hypertension Yes 20 62.5 19 59.4 0.798 
Hyperlipidemia Yes 9 28.1 9 28.1 1.000 
Ischemic heart disease Yes 11 35.5 6 18.8 0.135 
Opium addiction Yes 12 37.5 15 46.9 0.448 
Smoking Yes 12 37.5 14 43.8 0.661 
NIHSS 
Mild 15 46.9 16 50.0 
0.779 Moderate 16 50.0 14 43.8 
Severe 1 3.1 2 6.3 
Stenosis Yes 15 46.9 13 40.6 0.614 
 
 
Journal of Kerman University of Medical Sciences 2017, Vol. 24, Issue 6 
483 
Table 2. Peak systolic velocity in both groups  
Peak Systolic Velocity 
Placebo Group 
(n=32) 
Intervention Group 
 (n=32) P-value 
Mean SD Mean SD 
R CCA 
Before intervention 45.65 15.38 37.65 14.65 0.021 
After intervention 45.25 14.09 37.40 13.89 0.008 
R ICA 
Before intervention 42.62 13.71 37.96 14.96 0.100 
After intervention 42.68 12.54 35.93 13.19 0.020 
R MCA 
Before intervention 84.50 27.8 85.31 41.63 0.596 
After intervention 82.00 23.90 75.46 24.63 0.240 
R ACA 
Before intervention 71.31 31.12 70.75 35.49 0.804 
After intervention 69.21 31.07 57.46 15.97 0.138 
R PCA 
Before intervention 48.59 17.97 48.00 15.32 0.973 
After intervention 48.75 17.37 43.62 13.41 0.224 
R VA 
Before intervention 56.25 16.18 49.50 10.66 0.053 
After intervention 57.12 14.57 47.56 11.05 0.008 
L CCA 
Before intervention 41.71 12.27 38.96 12.94 0.387 
After intervention 43.71 12.22 40.09 13.62 0.256 
L ICA 
Before intervention 43.34 16.86 44.71 24.79 0.742 
After intervention 41.12 12.93 42.03 19.70 0.697 
L MCA 
Before intervention 86.96 27.49 86.65 27.35 0.941 
After intervention 82.81 20.43 80.15 21.39 0.532 
L ACA 
Before intervention 69.37 27.91 65.37 22.83 0.762 
After intervention 69.93 25.14 62.56 22.72 0.158 
L PCA 
Before intervention 48.28 15.63 52.90 21.87 0.310 
After intervention 48.40 14.90 47.40 12.93 0.904 
L VA 
Before intervention 59.00 22.43 51.56 16.03 0.083 
After intervention 61.06 24.00 46.87 9.96 0.002 
B A 
Before intervention 52.21 19.23 57.96 16.72 0.057 
After intervention 53.53 19.30 55.51 15.34 0.441 
Table 3. Mean flow velocity in both groups  
Mean Flow Velocity 
Placebo Group (n=32) Intervention Group (n=32) 
P-value 
Mean SD Mean SD 
R CCA 
Before intervention 17.21 4.85 16.65 5.83 0.291 
After intervention 17.65 5.56 16.40 5.38 0.123 
R ICA 
Before intervention 20.25 6.83 18.81 7.63 0.294 
After intervention 20.65 6.69 17.18 6.08 0.031 
R MCA 
Before intervention 51.12 19.33 52.68 30.41 0.680 
After intervention 50.68 17.90 43.28 12.91 0.085 
R ACA 
Before intervention 28.53 17.20 42.62 29.50 0.995 
After intervention 37.65 15.97 33.96 10.81 0.427 
R PCA 
Before intervention 27.09 11.25 26.31 6.34 0.819 
After intervention 27.34 11.35 23.68 5.13 0.247 
R VA 
Before intervention 30.06 9.90 27.06 6.99 0.167 
After intervention 31.15 9.72 25.71 7.11 0.058 
L CCA 
Before intervention 17.43 5.76 17.68 5.45 0.859 
After intervention 19.56 6.20 18.40 6.32 0.480 
L ICA 
Before intervention 20.65 6.50 24.50 18.71 0.835 
After intervention 20.96 7.21 20.71 10.84 0.400 
L MCA 
Before intervention 52.75 15.95 51.12 15.51 0.502 
After intervention 50.56 14.18 48.40 13.94 0.489 
L ACA 
Before intervention 39.28 14.28 37.03 10.29 0.472 
After intervention 39.84 12.37 33.06 9.36 0.033 
L PCA 
Before intervention 26.87 10.61 30.21 11.64 0.216 
After intervention 27.15 9.41 26.78 7.30 0.930 
L VA 
Before intervention 29.93 12.02 28.84 10.04 0.667 
After intervention 30.09 11.60 27.18 7.30 0.236 
BA 
Before intervention 27.03 11.64 35.06 11.60 0.004 
After intervention 27.75 12.31 31.51 9.52 0.109 
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